Edition: Global  
One News Page
“Probably the fastest-access news portal in the world”
> >

Some Teenagers Recreated Martin Shkreli's Crazy-Expensive Drug For $20

Huffington Post Thursday, 1 December 2016
When Martin Shkreli, the former CEO of Turing Pharmaceuticals, hiked up the price of a life-saving medication, one group of high school students saw an opportunity to do good.

Eight teenagers from Sydney Grammar School in Australia have collaborated with scientists from the University of Sydney to reproduce the active...
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 
Source: Newsy Studio - < > Embed

News video: Teenagers Recreate $750 Martin Shkreli Drug for $2 a Dose

Teenagers Recreate $750 Martin Shkreli Drug for $2 a Dose 01:16

A group of Australian students say they recreated the active ingredient in life-saving drug Daraprim for a fraction of its U.S. price.

You Might Like


Recent related news

Ex-drug executive Martin Shkreli wins separate fraud trial

Martin Shkreli, the former drug company executive who drew public outcry when he raised the price of a life-saving drug by 5,000 percent, will be tried for...
Raw Story - USAlso reported by •Reuters

Other recent news in Politics

Factbox: A report card on DONALD TRUMP's first 100 daysPentagon investigates MICHAEL FLYNN
FOX NEWS Host Jesse Watters Finally Gets In Trouble For SomethingTrump Agrees Not To Terminate NAFTA, To Renegotiate With CANADA, Mexico
After Ann Coulter Backs Out Of Visit, UC Berkeley Braces For FREE SPEECH RalliesTaliban: Spring Offensive Begins in AFGHANISTAN
Inside Kevin O’Leary’s last day as a CONSERVATIVE leadership candidateNew funding for Toronto transit, social housing left out of ONTARIO budget
ELIZABETH WARREN 'Troubled' Over Obama's Lucrative Wall Street SpeechBORIS JOHNSON Says UK Likely to Strike Syria if Asked by US

Twitter

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2017 One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter   FIND us on Google+